Abstract
Gene silencing via RNA interference (RNAi) is rapidly evolving as a personalized approach to cancer treatment. The effector molecules—small interfering RNAs (siRNAs) and microRNAs (miRNAs)—can be used to silence or “switch off” specific cancer genes. Currently, the main barrier to implementing siRNA- and miRNA-based therapies in clinical practice is the lack of an effective delivery system that can protect the RNA molecules from nuclease degradation, deliver to them to tumor tissue, and release them into the cytoplasm of the target cancer cells, all without inducing adverse effects. Here, we review the fundamentals of RNAi, cell membrane transport pathways, and factors that affect intracellular delivery. We discuss the advantages and disadvantages of the various types of nanoparticle delivery systems, with a focus on those that have been investigated in breast cancer in vivo.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahmad A, Mondal SK, Mukhopadhyay D, Banerjee R, Alkharfy KM (2016) Development of liposomal formulation for delivering anticancer drug to breast cancer stem-cell-like cells and its pharmacokinetics in an animal model. Mol Pharm 13(3):1081–1088. https://doi.org/10.1021/acs.molpharmaceut.5b00900
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y et al (2013) Liposome: classification, preparation, and applications. Nanoscale Res Lett 8(1):102. https://doi.org/10.1186/1556-276X-8-102
Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P (2002) Principles of membrane transport. In: Molecular biology of the cell, 4th edn. Garland Science, New York. https://www.ncbi.nlm.nih.gov/books/NBK26815. Accessed 29 Jul 2017
Arnold AE, Czupiel P, Shoichet M (2017) Engineered polymeric nanoparticles to guide the cellular internalization and trafficking of small interfering ribonucleic acids. J Control Release 259:3–15. https://doi.org/10.1016/j.jconrel.2017.02.019
Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V et al (2011) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24(2):157–167. https://doi.org/10.1038/modpathol.2010.200
Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH et al (2015) Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer 15:138. https://doi.org/10.1186/s12885-015-1121-4
Bai M, Shen M, Teng Y, Sun Y, Li F, Zhang X et al (2015) Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with ultrasound. Oncotarget 6(41):43779–43790. https://doi.org/10.18632/oncotarget.6085
Balazs DA, Godbey WT (2011) Liposomes for use in gene delivery. J Drug Deliv 2011:326497. https://doi.org/10.1155/2011/326497
Bannunah AM, Vllasaliu D, Lord J, Stolnik S (2014) Mechanisms of nanoparticle internalization and transport across an intestinal epithelial cell model: effect of size and surface charge. Mol Pharm 11(12):4363–4373. https://doi.org/10.1021/mp500439c
Bedi D, Gillespie JW, Petrenko VA Jr, Ebner A, Leitner M, Hinterdorfer P et al (2013) Targeted delivery of siRNA into breast cancer cells via phage fusion proteins. Mol Pharm 10(2):551–559. https://doi.org/10.1021/mp3006006
Behr JP (1997) The proton sponge: a trick to enter cells the viruses did not exploit. Chimia 51:34–36
Biswas S, Torchilin VP (2013) Dendrimers for siRNA delivery. Pharmaceuticals (Basel) 6(2):161–183. https://doi.org/10.3390/ph6020161
Bouclier C, Moine L, Hillaireau H, Marsaud V, Connault E, Opolon P et al (2008) Physicochemical characteristics and preliminary in vivo biological evaluation of nanocapsules loaded with siRNA targeting estrogen receptor alpha. Biomacromolecules 9(10):2881–2890. https://doi.org/10.1021/bm800664c
Boyle P (2012) Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 23(Suppl 6):vi7–vi12. https://doi.org/10.1093/annonc/mds187
Bulbake U, Doppalapudi S, Kommineni N, Khan W (2017) Liposomal formulations in clinical use: an updated review. Pharmaceutics 9(2):12. https://doi.org/10.3390/pharmaceutics9020012
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99(24):15524–15529. https://doi.org/10.1073/pnas.242606799
Carthew RW, Sontheimer EJ (2009) Origins and mechanisms of miRNAs and siRNAs. Cell 136(4):642–655. https://doi.org/10.1016/j.cell.2009.01.035
Chang M (2012) Tamoxifen resistance in breast cancer. Biomol Ther (Seoul) 20(3):256–267. https://doi.org/10.4062/biomolther.2012.20.3.256
Chien PY, Wang J, Carbonaro D, Lei S, Miller B, Sheikh S et al (2005) Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther 12(3):321–328. https://doi.org/10.1038/sj.cgt.7700793
Cho N (2016) Molecular subtypes and imaging phenotypes of breast cancer. Ultrasonography 35(4):281–288. https://doi.org/10.14366/usg.16030
Dahlman JE, Kauffman KJ, Langer R, Anderson DG (2014) Nanotechnology for in vivo targeted siRNA delivery. Adv Genet 88:37–69. https://doi.org/10.1016/B978-0-12-800148-6.00003-1
Dai X, Xiang L, Li T, Bai Z (2016) Cancer hallmarks, biomarkers and breast cancer molecular subtypes. J Cancer 7(10):1281–1294. https://doi.org/10.7150/jca.13141
Davis SS (1997) Biomedical applications of nanotechnology—implications for drug targeting and gene therapy. Trends Biotechnol 15(6):217–224
Deng ZJ, Morton SW, Ben-Akiva E, Dreaden EC, Shopsowitz KE, Hammond PT (2013) Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano 7(11):9571–9584. https://doi.org/10.1021/nn4047925
Ding Y, Wang Y, Zhou J, Gu X, Wang W, Liu C et al (2014) Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis. Biomaterials 35(25):7214–7227. https://doi.org/10.1016/j.biomaterials.2014.05.009
Dong D, Gao W, Liu Y, Qi XR (2015) Therapeutic potential of targeted multifunctional nanocomplex co-delivery of siRNA and low-dose doxorubicin in breast cancer. Cancer Lett 359(2):178–186. https://doi.org/10.1016/j.canlet.2015.01.011
Dou S, Yao YD, Yang XZ, Sun TM, Mao CQ, Song EW et al (2012) Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy. J Control Release 161(3):875–883. https://doi.org/10.1016/j.jconrel.2012.05.015
Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103(22):1656–1664. https://doi.org/10.1093/jnci/djr393
Draz MS, Fang BA, Zhang P, Hu Z, Gu S, Weng KC et al (2014) Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics 4(9):872–892. https://doi.org/10.7150/thno.9404
Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F et al (2013) Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res 15(5):R92. https://doi.org/10.1186/bcr3493
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411(6836):494–498
Eliyatkın N, Yalçın E, Zengel B, Aktaş S, Vardar E (2015) Molecular classification of breast carcinoma: from traditional, old-fashioned way to a new age, and a new way. J Breast Health 11(2):59–66. https://doi.org/10.5152/tjbh.2015.1669
Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A (2012) Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 38(6):698–707. https://doi.org/10.1016/j.ctrv.2011.11.005
Essex S, Navarro G, Sabhachandani P, Chordia A, Trivedi M, Movassaghian S et al (2015) Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors. Gene Ther 22(3):257–266. https://doi.org/10.1038/gt.2014.97
Falamarzian A, Xiong X-B, Uludag H, Lavasanifar A (2012) Polymeric micelles for siRNA delivery. J Drug Deliv Sci Technol 22:43–54. https://doi.org/10.1016/S1773-2247(12)50004-3
Fan W, Wang X, Ding B, Cai H, Wang X, Fan Y et al (2016) Thioaptamer-conjugated CD44-targeted delivery system for the treatment of breast cancer in vitro and in vivo. J Drug Target 24(4):359–371. https://doi.org/10.3109/1061186X.2015.1077850
Fang WB, Yao M, Brummer G, Acevedo D, Alhakamy N, Berkland C et al (2016) Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment. Oncotarget 7(31):49349–49367. https://doi.org/10.18632/oncotarget.9885
Finlay J, Roberts CM, Dong J, Zink JI, Tamanoi F, Glackin CA (2015a) Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. Nanomedicine 11(7):1657–1666. https://doi.org/10.1016/j.nano.2015.05.011
Finlay J, Roberts CM, Lowe G, Loeza J, Rossi JJ, Glackin CA (2015b) RNA-based TWIST1 inhibition via dendrimer complex to reduce breast cancer cell metastasis. Biomed Res Int 2015:382745. https://doi.org/10.1155/2015/382745
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669):806–811. https://doi.org/10.1038/35888
Gao K, Huang L (2009) Nonviral methods for siRNA delivery. Mol Pharm 6(3):651–658. https://doi.org/10.1021/mp800134q
Gao Y, Chen L, Zhang Z, Chen Y, Li Y (2011) Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles. Biomaterials 32(6):1738–1747. https://doi.org/10.1016/j.biomaterials.2010.11.001
Gasparri ML, Casorelli A, Bardhi E, Besharat AR, Savone D, Ruscito I et al (2017) Beyond circulating microRNA biomarkers: urinary microRNAs in ovarian and breast cancer. Tumor Biol 39(5):1010428317695525. https://doi.org/10.1177/1010428317695525
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3(4):524–548. https://doi.org/10.1001/jamaoncol.2016.5688
Goljan EF (2011) Rapid review pathology, 3rd edn. Mosby/Elsevier, Philadelphia
Gong C, Hu C, Gu F, Xia Q, Yao C, Zhang L et al (2017) Co-delivery of autophagy inhibitor ATG7 siRNA and docetaxel for breast cancer treatment. J Control Release 266:272–286. https://doi.org/10.1016/j.jconrel.2017.09.042
Govindarajan S, Sivakumar J, Garimidi P, Rangaraj N, Kumar JM, Rao NM et al (2012) Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide–affibody bioconjugate. Biomaterials 33(8):2570–2582. https://doi.org/10.1016/j.biomaterials.2011.12.003
Gu J, Fang X, Hao J, Sha X (2015) Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery. Biomaterials 45:99–114. https://doi.org/10.1016/j.biomaterials.2014.12.030
Guiu S, Michiels S, Andre F, Cortes J, Denkert C, Di Leo A et al (2012) Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 23(12):2997–3006. https://doi.org/10.1093/annonc/mds586
Gujrati M, Vaidya A, Lu ZR (2016) Multifunctional pH-sensitive amino lipids for siRNA delivery. Bioconjug Chem 27(1):19–35. https://doi.org/10.1021/acs.bioconjchem.5b00538
Hamilton AJ, Baulcombe DC (1999) A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 286(5441):950–952
Han HD, Mora EM, Roh JW, Nishimura M, Lee SJ, Stone RL et al (2011) Chitosan hydrogel for localized gene silencing. Cancer Biol Ther 11(9):839–845. https://doi.org/10.4161/cbt.11.9.15185
He Y, Park K (2016) Effects of the Microparticle Shape on Cellular Uptake. Mol Pharm 13(7):2164. https://doi.org/10.1021/acs.molpharmaceut.5b00992.
Hennigs A, Riedel F, Gondos A, Sinn P, Schirmacher P, Marmé F et al (2016) Prognosis of breast cancer molecular subtypes in routine clinical care: a large prospective cohort study. BMC Cancer 16(1):734. https://doi.org/10.1186/s12885-016-2766-3
Hirota K, Terada H (2012) Endocytosis of particle formulations by macrophages and its application to clinical treatment. In: Ceresa B (ed) Molecular regulation of endocytosis. InTech. https://doi.org/10.5772/45820. Available online at: https://www.intechopen.com/books/molecular-regulation-of-endocytosis/endocytosis-of-particle-formulations-by-macrophages-and-its-application-to-clinical-treatment
Ho EA, Osooly M, Strutt D, Masin D, Yang Y, Yan H et al (2013) Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model. J Pharm Sci 102(1):227–236. https://doi.org/10.1002/jps.23351
Hogrefe RI, Lebedev AV, Zon G, Pirollo KF, Rait A, Zhou Q et al (2006) Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2. Nucleosides Nucleotides Nucleic Acids 25(8):889–907. https://doi.org/10.1080/15257770600793885
Hon JD, Singh B, Sahin A, Du G, Wang J, Wang VY et al (2016) Breast cancer molecular subtypes: from TNBC to QNBC. Am J Cancer Res 6(9):1864–1872
Honary S, Zahir F (2013) Effect of zeta potential on the properties of Nano-drug delivery systems—a review (part 2). Trop J Pharm Res 12(2):265–273. https://doi.org/10.4314/tjpr.v12i2.20
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90. https://doi.org/10.3322/caac.20107
Jiang K, Li J, Yin J, Ma Q, Yan B, Zhang X et al (2015) Targeted delivery of CXCR4-siRNA by scFv for HER2(+) breast cancer therapy. Biomaterials 59:77–87. https://doi.org/10.1016/j.biomaterials.2015.04.030
Jing H, Cheng W, Li S, Wu B, Leng X, Xu S et al (2016) Novel cell-penetrating peptide-loaded nanobubbles synergized with ultrasound irradiation enhance EGFR siRNA delivery for triple negative breast cancer therapy. Colloids Surf B Biointerfaces 146:387–395. https://doi.org/10.1016/j.colsurfb.2016.06.037
Kim HJ, Kim A, Miyata K, Kataoka K (2016) Recent progress in development of siRNA delivery vehicles for cancer therapy. Adv Drug Deliv Rev 104:61–77. https://doi.org/10.1016/j.addr.2016.06.011
Kittaneh M, Montero AJ, Glück S (2013) Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer 5:61–70. https://doi.org/10.4137/BIC.S9455
Koval M, Preiter K, Adles C, Stahl PD, Steinberg TH (1998) Size of IgG-opsonized particles determines macrophage response during internalization. Exp Cell Res 242(1):265–273. https://doi.org/10.1006/excr.1998.4110
Kumar M, Yigit M, Dai G, Moore A, Medarova Z (2010) Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res 70(19):7553–7561. https://doi.org/10.1158/0008-5472.CAN-10-2070
Lam JK, Chow MY, Zhang Y, Leung SW (2015) siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids 4:e252. https://doi.org/10.1038/mtna.2015.23
Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5):843–854
Li Y, Kröger M, Liu WK. (2015) Shape effect in cellular uptake of PEGylated nanoparticles: comparison between sphere, rod, cube and disk. Nanoscale 7(40):16631-46. https://doi.org/10.1039/c5nr02970h.
Li J, Xue S, Mao Z-W (2016) Nanoparticle delivery systems for siRNA-based therapeutics. J Mater Chem B 4(41):6620–6639. https://doi.org/10.1039/c6tb01462c
Li X, Oprea-Ilies GM, Krishnamurti U (2017) New developments in breast cancer and their impact on daily practice in pathology. Arch Pathol Lab Med 141(4):490–498. https://doi.org/10.5858/arpa.2016-0288-SA
Liang W, Lam JKW (2012) Endosomal escape pathways for non-viral nucleic acid delivery systems. In: Ceresa B (ed) Molecular regulation of endocytosis. InTech. https://doi.org/10.5772/46006. Available online at: https://www.intechopen.com/books/molecular-regulation-of-endocytosis/endosomal-escape-pathways-for-non-viral-nucleic-acid-delivery-systems
Lin G, Zhu W, Yang L, Wu J, Lin B, Xu Y et al (2014) Delivery of siRNA by MRI-visible nanovehicles to overcome drug resistance in MCF-7/ADR human breast cancer cells. Biomaterials 35(35):9495–9507. https://doi.org/10.1016/j.biomaterials.2014.07.049
Liu Y, Zhu YH, Mao CQ, Dou S, Shen S, Tan ZB et al (2014) Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles. J Control Release 192:114–121. https://doi.org/10.1016/j.jconrel.2014.07.001
Liu H, Chang H, Lv J, Jiang C, Li Z, Wang F et al (2016) Screening of efficient siRNA carriers in a library of surface-engineered dendrimers. Sci Rep 6:25069. https://doi.org/10.1038/srep25069
Lü L, Mao X, Shi P, He B, Xu K, Zhang S et al (2017) MicroRNAs in the prognosis of triple-negative breast cancer: a systematic review and meta-analysis. Medicine (Baltimore) 96(22):e7085. https://doi.org/10.1097/MD.0000000000007085
Mai J, Huang Y, Mu C, Zhang G, Xu R, Guo X et al (2014) Bone marrow endothelium-targeted therapeutics for metastatic breast cancer. J Control Release 187:22–29. https://doi.org/10.1016/j.jconrel.2014.04.057
Maire V, Némati F, Richardson M, Vincent-Salomon A, Tesson B, Rigaill G et al (2013) Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Cancer Res 73(2):813–823. https://doi.org/10.1158/0008-5472.CAN-12-2633
Mao CQ, Du JZ, Sun TM, Yao YD, Zhang PZ, Song EW et al (2011) A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy. Biomaterials 32(11):3124–3133. https://doi.org/10.1016/j.biomaterials.2011.01.006
Martin V, Botta F, Zanellato E, Molinari F, Crippa S, Mazzucchelli L et al (2012). Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features. Histol Histopathol 27(6):785. https://doi.org/10.14670/HH-27.785.
Mastoraki A, Kazani A, Mastoraki S, Konstantiadou I, Kokoropoulos P, Smyrniotis V et al (2014) Breast-cancer subtyping in clinical practice: Clinicopathologic features and outcomes. J Gynecol Surg 30(5):260–264. https://doi.org/10.1089/gyn.2014.0022
Mattick JS (2001) Non-coding RNAs: the architects of eukaryotic complexity. EMBO Rep 2(11):986–991. https://doi.org/10.1093/embo-reports/kve230
Maximiano S, Magalhães P, Guerreiro MP, Morgado M (2016) Trastuzumab in the treatment of breast cancer. BioDrugs 30(2):75–86. https://doi.org/10.1007/s40259-016-0162-9
Mendelsohn J, Howley PM, Israel MA, Gray JW, Thompson CB (2015) The molecular basis of cancer, 4th edn. Saunders/Elsevier, Philadelphia, PA
Meng Z, Lu M (2017) RNA interference-induced innate immunity, off-target effect, or immune adjuvant? Front Immunol 8:331. https://doi.org/10.3389/fimmu.2017.00331
Meng H, Mai WX, Zhang H, Xue M, Xia T, Lin S et al (2013) Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 7(2):994–1005. https://doi.org/10.1021/nn3044066
Mikhaylova M, Stasinopoulos I, Kato Y, Artemov D, Bhujwalla ZM (2009) Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA. Cancer Gene Ther 16(3):217–226. https://doi.org/10.1038/cgt.2008.79
Morry J, Ngamcherdtrakul W, Gu S, Reda M, Castro DJ, Sangvanich T et al (2017) Targeted treatment of metastatic breast cancer by PLK1 siRNA delivered by an antioxidant nanoparticle platform. Mol Cancer Ther 16(4):763–772. https://doi.org/10.1158/1535-7163.MCT-16-0644
Navarro G, Pan J, Torchilin VP (2015) Micelle-like nanoparticles as carriers for DNA and siRNA. Mol Pharm 12(2):301–313. https://doi.org/10.1021/mp5007213
Ngamcherdtrakul W, Morry J, Gu S, Castro DJ, Goodyear SM, Sangvanich T et al (2015) Cationic polymer modified mesoporous silica nanoparticles for targeted SiRNA delivery to HER2+ breast cancer. Adv Funct Mater 25(18):2646–2659. https://doi.org/10.1002/adfm.201404629
Nourbakhsh M, Jaafari MR, Lage H, Abnous K, Mosaffa F, Badiee A, Behravan J (2015) Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer. Iranian J Basic Med Sci 18(4):385–392
Park DH, Jung BK, Lee YS, Jang JY, Kim MK, Lee JK et al (2015) Evaluation of in vivo antitumor effects of ANT2 shRNA delivered using PEI and ultrasound with microbubbles. Gene Ther 22(4):325–332. https://doi.org/10.1038/gt.2014.120
Parmar MB, Aliabadi HM, Mahdipoor P, Kucharski C, Maranchuk R, Hugh JC, Uludağ H (2015) Targeting cell cycle proteins in breast cancer cells with siRNA by using lipid-substituted polyethylenimines. Front Bioeng Biotechnol 3:14. https://doi.org/10.3389/fbioe.2015.00014
Parvani JG, Jackson MW (2017) Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles. Endocr Relat Cancer 24(4):R81–R97. https://doi.org/10.1530/ERC-16-0482
Penault-Llorca F, Radosevic-Robin N (2017) Ki67 assessment in breast cancer: an update. Pathology 49(2):166–171. https://doi.org/10.1016/j.pathol.2016.11.006
Peng C, Ma W, Xia W, Zheng W (2017) Integrated analysis of differentially expressed genes and pathways in triple-negative breast cancer. Mol Med Rep 15(3):1087–1094. https://doi.org/10.3892/mmr.2017.6101
Piao L, Li H, Teng L, Yung BC, Sugimoto Y, Brueggemeier RW et al (2013) Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer. Nanomedicine 9(1):122–129. https://doi.org/10.1016/j.nano.2012.03.008
Pietri E, Conteduca V, Andreis D, Massa I, Melegari E, Sarti S et al (2016) Androgen receptor signaling pathways as a target for breast cancer treatment. Endocr Relat Cancer 23(10):R485-98. https://doi.org/10.1530/ERC-16-0190.
Pirollo KF, Rait A, Zhou Q, Hwang SH, Dagata JA, Zon G et al (2007) Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res 67(7):2938–2943. https://doi.org/10.1158/0008-5472.CAN-06-4535
Pittella F, Kataoka K (2013) Polymeric micelles for siRNA delivery. In: RNA interference from biology to therapeutics, pp 161–184. https://doi.org/10.1007/978-1-4614-4744-3_8
Poteryaev D, Datta S, Ackema K, Zerial M, Spang A (2010) Identification of the switch in early-to-late endosome transition. Cell 141(3):497–508. https://doi.org/10.1016/j.cell.2010.03.011
Prokop A (2011) Intracellular delivery: fundamentals and applications, vol 5. Springer, Dordrecht
Rajput S, Puvvada N, Kumar BP, Sarkar S, Konar S, Bharti R et al (2015) Overcoming Akt induced therapeutic resistance in breast cancer through siRNA and thymoquinone encapsulated multilamellar gold niosomes. Mol Pharm 12(12):4214–4225. https://doi.org/10.1021/acs.molpharmaceut.5b00692
Ran R, Liu Y, Gao H, Kuang Q, Zhang Q, Tang J et al (2014) Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated hyaluronic acid for anti P-glycoprotein siRNA: a potential candidate for overcoming multi-drug resistance. Int J Pharm 477(1–2):590–600. https://doi.org/10.1016/j.ijpharm.2014.11.012
Ranftler M, Strasser-Weippl K (2017) New chemotherapies in breast cancer. Memo 10(3):127–131. https://doi.org/10.1007/s12254-017-0348-y
Raucher D, Ryu JS (2015) Cell-penetrating peptides: strategies for anticancer treatment. Trends Mol Med 21(9):560–570. https://doi.org/10.1016/j.molmed.2015.06.005
Redig AJ, McAllister SS (2013) Breast cancer as a systemic disease: a view of metastasis. J Intern Med 274(2):113–126. https://doi.org/10.1111/joim.12084
Richards DM, Endres RG (2016) Target shape dependence in a simple model of receptor-mediated endocytosis and phagocytosis. Proc Natl Acad Sci U S A 113(22):6113–6118. https://doi.org/10.1073/pnas.1521974113
Rothschild SI (2014) microRNA therapies in cancer. Mol Cell Ther 2:7. https://doi.org/10.1186/2052-8426-2-7
Siolas D, Lerner C, Burchard J, Ge W, Linsley PS, Paddison PJ et al (2005) Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol 23(2):227–231
Sioud M (2015) RNA interference: mechanisms, technical challenges, and therapeutic opportunities. Methods Mol Biol 1218:1–15
Sun P, Huang W, Jin M, Wang Q, Fan B, Kang L et al (2016) Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis. Int J Nanomedicine 11:4931–4945. https://doi.org/10.2147/IJN.S105427
Sun P, Huang W, Kang L, Jin M, Fan B, Jin H et al (2017a) siRNA-loaded poly(histidine-arginine)6-modified chitosan nanoparticle with enhanced cell-penetrating and endosomal escape capacities for suppressing breast tumor metastasis. Int J Nanomedicine 12:3221–3234. https://doi.org/10.2147/IJN.S129436
Sun H, Yarovoy I, Capeling M, Cheng C (2017b) Polymers in the co-delivery of siRNA and anticancer drugs for the treatment of drug-resistant cancers. Top Curr Chem 375(2):24. https://doi.org/10.1007/s41061-017-0113-z
Suter SR, Sheu-Gruttadauria J, Schirle NT, Valenzuela R, Ball-Jones AA, Onizuka K et al (2016) Structure-guided control of siRNA off-target effects. J Am Chem Soc 138(28):8667–8669. https://doi.org/10.1021/jacs.6b06137
Takahashi R, Miyazaki H, Ochiya T (2015) The roles of microRNAs in breast cancer. Cancers 7(2):598–616. https://doi.org/10.3390/cancers7020598
Tatiparti K, Sau S, Kashaw SK, Iyer AK (2017) siRNA delivery strategies: a comprehensive review of recent developments. Nanomaterials 7(4):77. https://doi.org/10.3390/nano7040077
Wakaskar RR (2017) Polymeric micelles for drug delivery. Int J Drug Dev Res 9:01–02
Walther W, Siegel R, Kobelt D, Knösel T, Dietel M, Bembenek A et al (2008) Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer. Clin Cancer Res 14(22):7545–7553. https://doi.org/10.1158/1078-0432.CCR-08-0412
Wang S, Cao M, Deng X, Xiao X, Yin Z, Hu Q et al (2015) Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy. Adv Healthcare Mater 4(2):281–290. https://doi.org/10.1002/adhm.201400222
Wang K, Kievit FM, Zhang M (2016a) Nanoparticles for cancer gene therapy: recent advances, challenges, and strategies. Pharmacol Res 114:56–66. https://doi.org/10.1016/j.phrs.2016.10.016
Wang F, Li C, Cheng J, Yuan Z (2016b) Recent advances on inorganic nanoparticle-based cancer therapeutic agents. Int J Environ Res Public Health 13(12):1182. https://doi.org/10.3390/ijerph13121182
Whitehead KA, Dorkin JR, Vegas AJ, Chang PH, Veiseh O, Matthews J et al (2014) Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat Commun 5:4277. https://doi.org/10.1038/ncomms5277
Wu J, Huang W, He Z (2013). Dendrimers as carriers for siRNA delivery and gene silencing: a review. Sci World J 2013:630654. https://doi.org/10.1155/2013/630654
Xie X, Lin W, Li M, Yang Y, Deng J, Liu H et al (2016) Efficient siRNA delivery using novel cell-penetrating peptide-siRNA conjugate-loaded nanobubbles and ultrasound. Ultrasound Med Biol 42(6):1362–1374. https://doi.org/10.1016/j.ultrasmedbio.2016.01.017
Yang Y, Xia X, Dong W, Wang H, Li L, Ma P et al (2016) Acid sensitive polymeric micelles combining folate and bioreducible conjugate for specific intracellular siRNA delivery. Macromol Biosci 16(5):759–773. https://doi.org/10.1002/mabi.201500389
Yersal O, Barutca S (2014) Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol 5(3):412–424. https://doi.org/10.5306/wjco.v5.i3.412
Yip CH, Bhoo-Pathy N, Daniel JM, Foo YC, Mohamed AK, Abdullah MM et al (2016) Roles of Ki67 in breast cancer—important for management? Asian Pac J Cancer Prev 17(3):1077–1082. https://doi.org/10.7314/apjcp.2016.17.3.1077
Young SWS, Stenzel M, Yang J (2016) Nanoparticle-siRNA: a potential cancer therapy? Crit Rev Oncol Hematol 98:159–169. https://doi.org/10.1016/j.critrevonc.2015.10.015
Yousefpour Marzbali M, Yari Khosroushahi A (2017) Polymeric micelles as mighty nanocarriers for cancer gene therapy: a review. Cancer Chemother Pharmacol 79(4):637–649. https://doi.org/10.1007/s00280-017-3273-1
Yu MZ, Pang WH, Yang T, Wang JC, Wei L, Qiu C et al (2016) Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer. Eur J Pharm Sci 92:39–48. https://doi.org/10.1016/j.ejps.2016.06.020
Zhu WJ, Yang SD, Qu CX, Zhu QL, Chen WL, Li F et al (2017) Low-density lipoprotein-coupled micelles with reduction and pH dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor. Int J Nanomedicine 12:3375–3393. https://doi.org/10.2147/IJN.S126310
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Tamkin Ahmadzada declares that she has no conflict of interest. Glen Reid declares that he has no conflict of interest. David McKenzie declares that he has no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Ahmadzada, T., Reid, G. & McKenzie, D. Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer. Biophys Rev 10, 69–86 (2018). https://doi.org/10.1007/s12551-017-0392-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12551-017-0392-1